Phosphatidylserine enriched with polyunsaturated n‐3 fatty acid supplementation for Attention‐Deficit Hyperactivity Disorder (ADHD) in children & adolescents with epilepsy: a randomized placebo‐controlled trial

Sylvain Rheims, Vania Herbillon, Ségolène Gaillard, Catherine Mercier, Nathalie Villeuve, Frédéric Villéga, Claude Cances, Pierre Castelnau, Silvia Napuri, Anne de Saint‐Martin, Stéphane Auvin, Sylvie N. Guyen The Tich, Patrick Berquin, Julitta de Bellecize, Mathieu Milh, Pascal Roy, Alexis Arzimanoglou, Jacques Bodennec, Laurent Bezin, Behrouz Kassai,
Epilepsia Open. 2024-01-03; :
DOI: 10.1002/epi4.12892

Lire sur PubMed


Attention‐Deficit Hyperactivity Disorder (ADHD) is a frequent comorbidity in children with epilepsy, which management mostly relies on the usual treatments of ADHD, especially methylphenidate. Supplementation with polyunsaturated n‐3 Fatty Acid (PUFA) has been proposed as an alternative therapeutic approach in ADHD without epilepsy but has never been evaluated in epilepsy‐associated ADHD.


A multicenter double blind randomized placebo‐controlled trial evaluating supplementation with PUFA, in eicosapentaenoic‐ and docosahexaenoic‐acid form, conjugated to a phospholipid vector (PS‐Omega3) in children aged > 6 and < 16‐years old and suffering from any type of epilepsy and ADHD (inattentive or combined type) according to DSM‐V. After a 4‐week baseline period, patients were allocated (1:1) either to placebo group or to PS‐Omega 3 group and entered a 12 week‐double‐blind treatment period which was followed by a 12 week‐open‐label treatment period. The primary outcome was the reduction of the ADHD‐rating scale IV attention‐deficit subscore after 12 weeks of treatment.


The study was stopped early because of lack of eligible participants and the expected sample size was not reached. Seventy‐four patients were randomized, 44 in PS‐Omega3 and 30 in the placebo group. The reduction after 12 weeks of treatment in the inattention subscore of the ADHD‐IV scale was ‐1.57 in the PS‐Omega3 group, and ‐2.90 in the placebo group (p = 0.33, α = 5%). Results were similar after 24 weeks of treatment and for all other ADHD‐related secondary outcomes, with no difference between placebo and PS‐Omega3.


Our study remaining underpowered, no formal conclusion about the effect of Ps‐Omega3 could be drawn. However, our data strongly suggested that the PS‐Omega 3 formulation used in the current study did not improve ADHD symptoms in children with epilepsy.

Auteurs Bordeaux Neurocampus